Profile of CHEMOCENTRYX INC(NASDAQ:CCXI) stock

CHEMOCENTRYX INC51.66

NASDAQ:CCXI (9/30/2022, 7:11:47 PM)0 (0%)

After market: 51.66 0 (0%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS Sector	Health Care
GICS Industry	Biotechnology

Chartmill FA Rating

Valuation		Growth
Profitability		Health
Dividend

Overview

Earnings (Last)	08-08 2022-08-08/amc	Earnings (Next)	11-07 2022-11-07
Ins Owners	4.38%	Inst Owners	81.76%
Market Cap	3.69B	Shares	71.36M
PE	N/A	Fwd PE	N/A
Dividend Yield	N/A	Analysts	52.31
IPO	02-08 2012-02-08

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

ChemoCentryx, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines. The company is headquartered in San Carlos, California and currently employs 178 full-time employees. The company went IPO on 2012-02-08. The firm is targeting the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. Its development pipelines include TAVNEOS and Immuno-Oncology. TAVNEOS is for the treatment of severe hidradenitis suppurativa (HS) and seeks to advance TAVNEOS into Phase III clinical development for the treatment of severe HS. The firm's CCX559 is orally-administered investigational inhibitor for programmed death protein 1/programmed death-ligand 1 (PD-1/PD-L1), which is developing for the treatment of various cancers. The company markets TAVNEOS (avacopan) as an adjunctive treatment for adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis associated vasculitis, specifically granulomatosis with polyangiitis and microscopic polyangiitis.

Company Info

CHEMOCENTRYX INC

835 Industrial Road, Suite 600

San Carlos CALIFORNIA 94043

P: 16502102900.0

CEO: Thomas J. Schall

Employees: 178

Website: https://www.chemocentryx.com/

CCXI News

12 days ago - Investor's Business DailyHere Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This Year

The biotech run off a June bottom is great — until you realize you could've netted more.

16 days ago - Investor's Business DailySomething Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin

The market is struggling, yet biotech stocks are acting like it's good times again. Here's why.

17 days ago - Halper Sadeh LLPSHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CYBE, CCXI, AVLR

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...